Physician profile
David L Pollifrone
NPI 1215901574
$3,540.41
in general payments reported to CMS, 2019-2025
19 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $127 · 2021: $126 · 2022: $413 · 2023: $1,099 · 2024: $682 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991 · Education: $9.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.48 |
| Education | $9.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,554.49 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $651.31 | 2019-2023 | Myrbetriq |
| Urovant Sciences INC | $253.61 | 2022 | |
| Pfizer INC. | $195.35 | 2019-2024 | |
| Abbvie INC. | $194.03 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $178.90 | 2019-2023 | Aveed, Xiaflex |
| Boston Scientific Corporation | $124.93 | 2022-2025 | General - Erectile Dysfunction |
| Blue Earth Diagnostics | $72.75 | 2019-2022 | |
| Allergan, INC. | $65.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.50 | 2019-2022 | |
| Coloplast Corp | $40.29 | 2020 | |
| Axonics, INC. | $36.02 | 2023 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $27.36 | 2019-2023 | Erleada |
| Laborie Medical Technologies Corp. | $25.99 | 2023 | |
| Ferring Pharmaceuticals INC. | $25.23 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $21.04 | 2019 | |
| Myriad Genetic Laboratories, INC. | $18.60 | 2022 | |
| Travere Therapeutics, INC. | $9.38 | 2025 | Thiola |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,399.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pollifrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.